- Home
- STHO vs NKTX Comparison
STHO vs NKTX Comparison
Compare STHO & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STHO
- NKTX
- Stock Information
- Founded
- STHO N/A
- NKTX 2015
- Country
- STHO United States
- NKTX United States
- Employees
- STHO N/A
- NKTX N/A
- Industry
- STHO Real Estate
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- STHO Real Estate
- NKTX Health Care
- Exchange
- STHO Nasdaq
- NKTX Nasdaq
- Market Cap
- STHO 112.7M
- NKTX 123.5M
- IPO Year
- STHO N/A
- NKTX 2020
- Fundamental
- Price
- STHO $7.55
- NKTX $2.38
- Analyst Decision
- STHO
- NKTX Strong Buy
- Analyst Count
- STHO 0
- NKTX 5
- Target Price
- STHO N/A
- NKTX $13.50
- AVG Volume (30 Days)
- STHO 40.3K
- NKTX 1.1M
- Earning Date
- STHO 11-05-2025
- NKTX 11-06-2025
- Dividend Yield
- STHO N/A
- NKTX N/A
- EPS Growth
- STHO N/A
- NKTX N/A
- EPS
- STHO N/A
- NKTX N/A
- Revenue
- STHO $113,989,000.00
- NKTX N/A
- Revenue This Year
- STHO N/A
- NKTX N/A
- Revenue Next Year
- STHO N/A
- NKTX N/A
- P/E Ratio
- STHO N/A
- NKTX N/A
- Revenue Growth
- STHO N/A
- NKTX N/A
- 52 Week Low
- STHO $6.06
- NKTX $1.31
- 52 Week High
- STHO $13.23
- NKTX $4.55
- Technical
- Relative Strength Index (RSI)
- STHO 34.08
- NKTX 55.34
- Support Level
- STHO $7.43
- NKTX $2.27
- Resistance Level
- STHO $8.00
- NKTX $2.74
- Average True Range (ATR)
- STHO 0.29
- NKTX 0.18
- MACD
- STHO -0.04
- NKTX 0.02
- Stochastic Oscillator
- STHO 15.15
- NKTX 49.31
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties and land and development properties.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.